K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
K36 Therapeutics, Inc. (“K36”), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins…
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its…
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it has entered into a purchase…
